McGill University Health Centre
Welcome,         Profile    Billing    Logout  
 277 Trials 
340 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, Site Public
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting
3
77
Europe, Japan, US, RoW
TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930
Takeda, Takeda Development Center Americas, Inc., Shire
Thrombotic Thrombocytopenic Purpura (TTP)
03/27
03/27
NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection

Recruiting
3
80
Europe, Japan, US, RoW
Maribavir, TAK-620
Takeda, Takeda Development Center Americas, Inc.
Cytomegalovirus (CMV)
11/26
11/26
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting
3
240
Europe, Canada, Japan, US, RoW
Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention
Takeda, Takeda Development Center Americas, Inc.
Ulcerative Colitis, Crohn's Disease
08/31
08/31
NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Recruiting
2/3
75
US
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Takeda, Takeda Development Center Americas, Inc.
Primary Immunodeficiency Diseases (PID)
02/26
09/26
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT06031259: Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Recruiting
2/3
8
Europe, Canada
Idursulfase-IT, Elaprase
Takeda
Hunter Syndrome
01/34
06/34
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Recruiting
2
108
Canada, US, RoW
Placebo, TAK-101, TIMP-GLIA, Gluten
Takeda
Celiac Disease
10/25
10/25
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT05814016: A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Recruiting
2
180
US
Danavorexton, TAK-925, Placebo
Takeda
Sleep Apnea
01/25
03/25
NCT05469802: A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Withdrawn
2
78
US
Purified Inactivated Zika Virus Vaccine (PIZV), TAK-426, Placebo
Takeda
Healthy Volunteers
07/24
07/24
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Active, not recruiting
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
08/24
08/24
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
NCT02616302 / 2014-004506-15: A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children

Recruiting
2
70
Europe, Canada, US, RoW
Dexlansoprazole, Dexilant
Takeda
Gastroesophageal Reflux Disease (GERD)
01/25
01/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Recruiting
2
40
Europe, US, RoW
TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Takeda, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
03/25
03/25
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Active, not recruiting
2
357
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
05/25
05/25
NCT05673785: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Recruiting
2
52
RoW
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Takeda
Lymphoma
07/25
12/27
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Recruiting
2
138
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
08/25
08/25
NCT05890352: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recruiting
2
227
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Tazemetostat, E7438, EPZ-6438, EPZ6438, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
SWOG Cancer Research Network, National Cancer Institute (NCI), BeiGene, Ipsen, Incyte Corporation
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
12/26
01/29
NCT02615184 / 2014-004507-73: A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children

Recruiting
2
76
Europe, Canada, US, RoW
Dexlansoprazole, Dexilant
Takeda
Erosive Esophagitis
11/27
11/27
TAK-007-2001, NCT05020015: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting
2
27
US
TAK-007, Chemotherapy Agents
Takeda
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
10/25
06/30
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
1/2
27
Canada, US
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
08/23
11/23
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Completed
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
11/23
11/23
iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1/2
336
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda
Multiple Myeloma
02/24
09/24
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Active, not recruiting
1/2
68
Europe, US, RoW
Ponatinib, Ponatinib AAF, Chemotherapy Agents
Takeda, Takeda Development Center Americas, Inc.
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
12/24
01/27
NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Recruiting
1/2
182
Europe, Canada, US, RoW
TAK-280
Takeda, Takeda Development Center Americas, Inc.
Unresectable Locally Advanced or Metastatic Cancer
02/25
07/26
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1/2
58
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
03/25
03/25
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
EXCLAIM, NCT02716116 / 2016-001271-68: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Checkmark Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021
May 2021 - May 2021: Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021
Checkmark For EGFR Exon20 insertion+ metastatic 2L NSCLC
Jan 2021 - Jan 2021: For EGFR Exon20 insertion+ metastatic 2L NSCLC
Active, not recruiting
1/2
334
Europe, Japan, US, RoW
TAK-788, AP32788
Takeda
Carcinoma, Non-Small-Cell Lung
03/25
03/25
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Recruiting
1/2
258
US, RoW
TAK-186, MVC-101
Takeda
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
09/25
11/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
368
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
53
US
GDX012, Chemotherapy Agents
Takeda
Leukemia
04/26
06/27
NCT04964258: A Study of TAK-105 in Healthy Adults

Completed
1
80
US
TAK-105-a, TAK-105-a Placebo, TAK-105-b, TAK-105-b Placebo
Takeda
Healthy Volunteers
06/23
06/23
NCT05818956: A Study of TAK-227 in Healthy Adults

Completed
1
24
US
TAK-227
Takeda
Healthy Volunteers
06/23
06/23
NCT05602818: A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Completed
1
67
US
Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo
Takeda
Healthy Volunteers
06/23
07/23
NCT05995249: A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed
1
172
US
TAK-279, Erythromycin, Phenytoin, Efavirenz
Takeda
Healthy Volunteers
12/23
12/23
NCT06132867: A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

Completed
1
12
US
Brigatinib, ALUNBRIG®
Takeda
Healthy Volunteers
02/24
02/24
NCT04879849: A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Completed
1
34
US
Pembrolizumab, TAK-676, Image-guided radiation therapy
Takeda
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
04/24
04/24
NCT06258265: A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Recruiting
1
120
US
TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
Takeda
Healthy Volunteers
06/24
07/24
NCT05976321: A Study of TAK-279 in Adults With or Without Liver Damage

Recruiting
1
32
US
TAK-279
Takeda
Hepatic Impairment, Healthy Volunteers
08/24
08/24
MT-0169-001, NCT04017130: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Terminated
1
14
US
MT-0169
Molecular Templates, Inc.
Relapsed and/or Refractory Multiple Myeloma
12/23
12/23
NCT05976334: An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1
10
Europe
[14C] Subasumstat, TAK-981, Subasumstat
Takeda
Solid Tumors
08/24
04/25
NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Not yet recruiting
1
20
NA
TAK-007, Chemotherapy Agents
Takeda
Refractory Lupus Nephritis
04/29
04/29
NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Recruiting
1
24
RoW
TAK-279, Placebo
Takeda
Healthy Volunteers
12/24
12/24
NCT05992155: A Study of TAK-279 in Adults With or Without Kidney Problems

Completed
1
24
US
TAK-279
Takeda
Renal Impairment, Healthy Volunteers
05/24
05/24
NCT05891158: A Study About Fazirsiran in People With and Without Liver Problems

Recruiting
1
41
Europe
Fazirsiran, TAK-999
Takeda
Hepatic Impairment
04/25
04/25
iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Active, not recruiting
1
120
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda
Multiple Myeloma
01/24
06/24
NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Active, not recruiting
1
50
US
IGM-7354
IGM Biosciences, Inc.
Solid Tumor
02/26
03/26
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting
1
16
Europe, Japan, US, RoW
Mezagitamab, TAK-079
Takeda
Kidney Disease, Glomerulonephritis
03/26
03/26
NCT04506619 / 2020-002726-84: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Terminated
N/A
26
Europe, US
No Intervention
Oak Hill Bio Ltd
Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
08/22
08/22
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
INTUITION-CPF, NCT04844593: A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease

Completed
N/A
32
Europe
Takeda
Crohn Disease, Rectal Fistula
02/23
04/24
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Available
N/A
Europe, US, RoW
Idursulfase-IT, HGT-2310, TAK-609
Takeda
Hunter Syndrome
 
 
NCT05265078: A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

Completed
N/A
102
Europe
Takeda
Von Willebrand Disease (VWD)
04/23
04/23
DOrianT, NCT04659798: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

Completed
N/A
240
Europe
Takeda
Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
04/23
08/23
NCT04877431: A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

Completed
N/A
45
RoW
Takeda
Short Bowel Syndrome
06/23
06/23
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
TAK-743-4008, NCT04955964: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed
N/A
48
RoW
Takeda
Angioedemas, Hereditary
08/23
08/23
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Completed
N/A
76
Europe
Takeda
Non-small Cell Lung Cancer (NSCLC)
09/23
09/23
NCT05695560: A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers

Completed
N/A
12
Canada
No Intervention
Takeda
Von Willebrand Disease (VWD)
11/23
11/23
REALM, NCT05506774: A Study of People With CD30 Positive Lymphoma in China

Active, not recruiting
N/A
2800
RoW
Takeda
Lymphoma
12/24
12/24
NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Recruiting
N/A
100
Europe
No Intervention
Takeda
Hereditary Angioedema (HAE)
06/24
06/24
PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Recruiting
N/A
150
Canada
No Intervention
Takeda
Hereditary Angioedema (HAE), Angioedema
03/24
06/24
NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed
N/A
341
RoW
ADYNOVATE, PEGylated rFVIII
Takeda, Takeda Pharma Korea Co. Ltd.
Hemophilia A
01/24
01/24
NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

Completed
N/A
120
Europe, RoW
Takeda
Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative
03/24
03/24
CREDIT, NCT05288491: A Study of Chinese Adults With Lymphoma

Recruiting
N/A
1000
RoW
Takeda
Lymphoma
06/24
06/24
NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Recruiting
N/A
100
Canada
Non-interventional Study
Takeda
Short Bowel Syndrome (SBS)
07/24
07/24
NCT05106764: Early Detection of Fabry Disease

Active, not recruiting
N/A
50
Europe
No intervention
Takeda
Fabry Disease
04/24
04/24
NCT04861233: A Study of Lubiprostone to Treat Constipation

Recruiting
N/A
3000
RoW
No Intervention
Jeil Pharmaceutical Co., Ltd.
Constipation
05/24
11/24
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Active, not recruiting
N/A
500
RoW
Takeda
Colitis, Ulcerative, Crohn Disease
07/24
07/24
DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain

Recruiting
N/A
250
Europe
No intervention
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
05/24
05/24
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Recruiting
N/A
165
RoW
No Intervention
Takeda
Multiple Myeloma
06/24
06/24
NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin

Recruiting
N/A
50
Europe
No intervention
Takeda
T-Cell Lymphoma
06/24
06/24
mECHromatic, NCT05755568: A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn
N/A
30
Europe
No Intervention
Takeda
Metachromatic Leukodystrophy (MLD)
07/24
07/24
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Not yet recruiting
N/A
130
RoW
No intervention
Takeda
Hereditary Angioedema (HAE)
08/25
08/25
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Active, not recruiting
N/A
140
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
09/24
09/24
LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

Recruiting
N/A
576
Europe, Canada
Takeda
Attention Deficit Hyperactivity Disorder (ADHD)
09/24
09/24
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Recruiting
N/A
3000
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn
N/A
200
RoW
No Intervention
Takeda
Hodgkin Lymphoma
10/24
10/24
ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China

Withdrawn
N/A
10800
RoW
No Intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Recruiting
N/A
1000
RoW
No Intervention
Takeda
Lymphoma
01/25
01/25
SUNRISE, NCT05192863: A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting
N/A
72
Europe, Canada, RoW
No Intervention
Takeda
Crohn's Disease
01/25
01/25
PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

Completed
N/A
11
US
Standard of Care, SOC
Takeda
Gaucher Disease
04/23
04/23
NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Recruiting
N/A
2160
RoW
No Intervention
Takeda
Ulcerative Colitis, Crohn's Disease
01/25
01/25
HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Recruiting
N/A
100
Europe, RoW
No Intervention
Takeda
Multiple Myeloma, Secondary Immunodeficiency (SID)
07/25
03/26
LEADER, NCT04985643: A Study of Real Life Treatment for Multiple Myeloma (MM)

Recruiting
N/A
111
RoW
Takeda
Multiple Myeloma
08/25
08/25
VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting
N/A
165
Europe
Takeda
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
08/25
08/25
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Recruiting
N/A
320
RoW
No intervention
Takeda
Multiple Myeloma
10/25
10/25
 

Download Options